VIRTUAL
POSTER ROOM
CLICK ANYWHERE TO CONTINUE
Per the approved VALTOCO® (diazepam nasal spray) prescribing information, a second dose, when required, may be administered at least 4 hours after the initial dose. The use of a second dose within 4 hours has not been approved by the U.S. Food and Drug Administration (FDA). Please see the prescribing information (PI), including Boxed Warning, for additional important safety and use information.
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older. VALTOCO is under investigation for the use in children under 6 years; the efficacy and safety for this use have not been demonstrated. Please see the prescribing information (PI), including Boxed Warning, for additional important safety and use information.
Request a Follow Up
Request More Information
Downloads
Final Safety
and Effectiveness Results
Pediatric Study Design
Timing of Doses
Specific Subgroups
Tolerability Endpoints
of Clinical Interest
School Nurse
Current Practices
Quality of Life Results
Lack of Tolerance
